Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV002420270 | SCV002725046 | pathogenic | Hereditary cancer-predisposing syndrome | 2022-06-03 | criteria provided, single submitter | clinical testing | The p.L698* pathogenic mutation (also known as c.2093T>G), located in coding exon 15 of the APC gene, results from a T to G substitution at nucleotide position 2093. This changes the amino acid from a leucine to a stop codon within coding exon 15. This alteration occurs at the 3' terminus of theAPC gene, is not expected to trigger nonsense-mediated mRNA decay, and impacts the last 2146 amino acids of the protein. However, premature stop codons are typically deleterious in nature and the impacted region is critical for protein function and a significant portion of the protein is affected (Ambry internal data). This mutation has been reported in patients and families with familial adenomatous polyposis (FAP) (Soravia C et al. Am J Pathol, 1999 Jan;154:127-35; Delker DA et al. Cancer Prev Res (Phila), 2018 01;11:4-15). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation. |
Myriad Genetics, |
RCV003337294 | SCV004045717 | pathogenic | Familial adenomatous polyposis 1 | 2023-05-04 | criteria provided, single submitter | clinical testing | This variant is considered pathogenic. This variant creates a termination codon and is predicted to result in premature protein truncation. |
Department of Pathology and Laboratory Medicine, |
RCV000502286 | SCV000591106 | pathogenic | not provided | no assertion criteria provided | clinical testing | #N/A |